Medpace Holdings (MEDP) EBITDA (2015 - 2026)

Medpace Holdings (MEDP) has 12 years of EBITDA data on file, last reported at $146.8 million in Q2 2026.

• Quarterly EBITDA rose 16.22% year-over-year to $146.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $583.4 million (up 22.18% YoY) and the FY2025 annual result came in at $534.9 million, up 19.71% from the prior year.
• EBITDA rose to $146.8 million in Q2 2026, from $141.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $153.3 million in Q4 2025 to a low of $60.2 million in Q2 2022.
• A 5-year average of $104.8 million and a median of $104.6 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA jumped 44.89% — and 2025, when it advanced 9.08%.
• Tracing MEDP's EBITDA over 5 years: stood at $76.4 million in 2022, then grew by 14.25% to $87.3 million in 2023, then jumped by 43.58% to $125.4 million in 2024, then increased by 22.25% to $153.3 million in 2025, then dropped by 4.21% to $146.8 million in 2026.
• The last three EBITDA figures came in at $146.8 million (Q2 2026), $141.5 million (Q1 2026), and $153.3 million (Q4 2025), per Business Quant data.